HIV infection

Overview

HIV infection is a chronic viral disease caused by human immunodeficiency virus, a retrovirus that targets the immune system, especially CD4+ T cells. Without effective treatment, progressive immune depletion leads to acquired immunodeficiency syndrome (AIDS) and susceptibility to opportunistic infections, malignancies, and multi-organ complications. In modern care, antiretroviral therapy is central to suppressing viral replication, restoring immune function, and reducing transmission.

Biologically, HIV infection is characterized by persistent viral replication, immune activation, and long-term inflammatory and immunologic consequences even in treated individuals. Recent research continues to examine how viral suppression, immune exhaustion, inflammation, mitochondrial function, telomere attrition, and comorbid disease contribute to outcomes such as frailty, cardiac dysfunction, neurocognitive injury, and age-related health decline. Studies also increasingly focus on adherence, engagement in care, and prevention strategies, including future vaccine development and long-acting antibody approaches.

Recent Publications Summary

Recent publications on HIV infection have focused on intervention modeling, prevention, treatment engagement, and complications across diverse populations. A methodological paper from the NCIPHER Lab described empirical and simulation approaches for estimating causal intervention effects in real-world networked settings, emphasizing spillover through social and healthcare networks; the authors noted that accounting for spillover improved understanding of HIV intervention effectiveness, including in a transmission reduction project in Athens, Greece 42348626Jun. Another mixed-methods protocol, ENGAGE, was designed to optimize prevention of vertical HIV transmission among pregnant and postpartum adolescent girls and young women living with HIV in Tanzania, addressing the high burden of teenage pregnancy, poorer adherence and retention, and elevated infant transmission risk in sub-Saharan Africa 42315270Jun.

Several studies examined clinical management and outcomes in people living with HIV. A 10-year retrospective study in South Korea investigated factors associated with low-level viremia and their relationship to clinical outcomes, reflecting ongoing challenges in sustaining viral suppression with antiretroviral therapy 42302078Jun. In treatment-naïve people living with HIV, an ocular study assessed posterior segment findings and virologic-immunologic predictors, including cytomegalovirus retinitis and HIV-related retinopathy 42200741May. A case report described erythrovirus B19-induced pure red cell aplasia as the presenting feature that led to a new diagnosis of untreated HIV infection; the patient had advanced immunosuppression and was started on antiretroviral therapy with tenofovir, lamivudine, and dolutegravir, along with trimethoprim-sulfamethoxazole prophylaxis and folic acid supplementation 42154736May.

Other publications addressed psychosocial and contextual factors affecting people with HIV. A randomized controlled trial evaluated expressive writing as an intervention to improve optimism and coping among newly diagnosed people with HIV 42216406May. A study in Vietnam assessed the perceived impacts of the COVID-19 pandemic on adolescents living with HIV aged 10–15 years and their families, highlighting vulnerability to disruption during public health emergencies 42192372May. In addition, a study from South Africa examined gendered patterns of suboptimal care engagement among tuberculosis patients who completed treatment, relevant to HIV because of the overlapping burden of TB and HIV in affected populations 41417651Dec.

Prevention-related attitudes were also explored in LGBTQ adults during the mpox outbreak. In a cross-sectional survey, intent to vaccinate for HIV was associated with mpox vaccination intent/uptake, and higher mpox concern, greater HIV vaccination intent, and employment were associated with higher odds of mpox vaccination intent/uptake, suggesting shared outbreak-specific prevention orientations 42223400Jun.

What Changes, What Holds

1. Spillover must be counted when judging HIV intervention effects
METHOD Empirical and simulation work here changes how intervention impact is estimated in networked settings, because ignoring spillover can misstate effectiveness. That does not alter the chronic viral disease model in the Overview; it refines how prevention and transmission-reduction programs are evaluated, especially where social and healthcare connections spread effects beyond directly treated individuals 42348626Jun. The vertical-transmission optimization protocol in adolescents and young women adds a second methodological direction for prevention planning 42315270Jun.

2. Low-level viremia remains a practical obstacle to durable suppression
REINFORCES The retrospective findings sharpen, rather than revise, the Overview’s point that antiretroviral therapy is central but not always fully suppressive. Ongoing low-level viremia continues to matter clinically because it marks incomplete control despite treatment, and the accompanying ocular and case-report data fit the same picture of advanced or untreated infection producing organ-specific complications 42302078Jun42200741May. The new material strengthens attention to monitoring and early treatment, not a new disease mechanism.

3. HIV care is still vulnerable to psychosocial disruption and stigma-linked context
NEW DIRECTION These studies extend the Overview into areas it does not explicitly cover: coping support, adolescent family burden during COVID-19, and gendered care-engagement patterns in overlapping TB/HIV settings. They do not challenge viral pathogenesis or antiretroviral therapy, but they show that outcomes depend on behavioral and social conditions that can undermine diagnosis, retention, and resilience 42216406May42192372May. That widens HIV infection from a biomedical condition to one shaped by crisis and context.

4. Prevention attitudes may cluster across outbreak-specific vaccines
NEW DIRECTION The survey adds a behavioral-prevention link the Overview does not discuss: willingness to accept an HIV vaccine appears tied to mpox vaccination intent and uptake in LGBTQ adults. This does not revise the established account of HIV infection itself, but it suggests that vaccine readiness may be shared across emerging infectious threats, which could matter for future prevention campaigns 42223400Jun. The finding is associative, so it should be treated as a planning signal rather than a settled causal rule.

Overview update candidates: spillover-aware intervention evaluation; persistent low-level viremia as an ongoing management issue; psychosocial and contextual determinants of HIV care engagement; cross-vaccine prevention attitudes in LGBTQ adults.